![Blocking PHGDH in tumors that overexpress it halts cell proliferation and cancer growth in vitro and in vivo. [© Arto - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/July14_2011_17369713_BreastCancerPinkRibbon_BreastCancerBresearchEnzyme1951905819-218x150.jpg "Regenerative Collagen Scaffold Offers Better Options for Reconstruction of Soft Tissue in Surgery")
Ted W. Love, MD, president and CEO of Global Blood Therapeutics (GBT), defended the list price of his company’s recently-approved sickle-cell disease drug Oxbryta™ (voxelotor) before an audience of investors in New York . . .
Global Blood Therapeutics CEO Defends Price of Sickle-Cell Drug Oxbryta
Ted W. Love, MD, Details Company’s Sickle Cell Disease Approach, Defends Industry
Ted W. Love, MD, President and CEO of Global Blood Therapeutics (GBT), says the efficacy of Oxbryta™ and its pricing below the average for orphan drugs are among justifications for its $125,000-a-year cost, rejecting criticism over the drug’s price from the nonprofit Institute for Clinical and Economic Review (ICER). [Global Blood Therapeutics via YouTube]
![Scientists find key target for developing potential Group A Streptococcus vaccine or antibiotic. [NIAID]](https://www.genengnews.com/wp-content/uploads/2018/08/Sep19_2017_NIAID_GroupAStreptococcus_6001785221315-100x70.jpg "New Approach Might Provide Potential Treatment for Flesh-Eating Bacteria")